{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:36:00Z","timestamp":1783478160736,"version":"3.55.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Department of Science and Technology of Sichuan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Purpose:<\/jats:bold> A systematic review and meta-analysis was conducted to combine the data available from clinical trials and evaluate the clinical efficacy and safety of tirzepatide in people with type 2 diabetes (T2D).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We systematically searched the MEDLINE, Embase, Cochrane Library, and clinical trials registries (<jats:ext-link>https:\/\/clinicaltrials.gov<\/jats:ext-link>) up to 25 March 2022 for randomized controlled trials (RCTs) that compared tirzepatide with placebo or active hypoglycemic drugs in subjects with T2D. Heterogeneity was judged by the <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> value and Cochran\u2019s Q test. The randomized effects model was adopted to calculate risk ratios and weighted mean differences (WMDs). The primary outcome was the change from baseline in HbA1c levels. Secondary efficacy endpoints were fasting serum glucose (FSG), change of body weight, blood pressure, fasting lipid profiles, and safety indexes.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Six trials comprising 6,579 subjects (4,410 in the tirzepatide group and 2,054 in the control group) fulfilled the pre-specified criteria and were included in the study. Tirzepatide treatment resulted in reducing HbA1c (WMD: -1.07%; 95% confidence intervals [CIs]: \u22121.44, \u22120.56), FSG (WMD, \u221221.50\u00a0mg\/dl; 95% CI: \u221234.44, \u22128.56), body weight (WMD: \u22127.99 kg; 95% CI \u221211.36, \u22124.62), and blood pressure and ameliorated fasting lipid profiles, without increasing hypoglycemia, either as monotherapy or an add-on therapy. Tirzepatide increased the risk of gastrointestinal adverse events mainly in add-on therapy but not in terms of pancreatitis or cholelithiasis. Furthermore, tirzepatide presented a dose\u2013response effect on the reduction in HbA1c and body weight and increase in nausea and vomiting.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> In patients with type 2 diabetes, tirzepatide shows superior blood glucose control and weight loss performance, without an increased risk of hypoglycemia.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold> (<jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO<\/jats:ext-link>), identifier (CRD42022319442).<\/jats:p>","DOI":"10.3389\/fphar.2022.1016639","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T14:37:29Z","timestamp":1670510249000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Yan","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1002\/oby.20660","article-title":"Expert Panel Report: Guidelines (2013) for the management of overweight and obesity in adults","volume":"22","year":"2014","journal-title":"Obes. (Silver Spring)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3390\/ph14100991","article-title":"Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized phase II\/III trials","volume":"14","author":"Bhagavathula","year":"2021","journal-title":"Pharm. (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur. Heart J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metab."},{"key":"B5","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: The SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"807548","DOI":"10.3389\/fphar.2021.807548","article-title":"Trends in antidiabetic drug discovery: FDA approved drugs, new drugs in clinical trials and global sales","volume":"12","author":"Dahlen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): A randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.2337\/dc22-S008","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of medical care in diabetes-2022","volume":"45","author":"Draznin","year":"","journal-title":"Diabetes Care"},{"key":"B9","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/dc22-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2022","volume":"45","author":"Draznin","year":"","journal-title":"Diabetes Care"},{"key":"B10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.4103\/ijem.ijem_423_21","article-title":"Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis","volume":"25","author":"Dutta","year":"2021","journal-title":"Indian J. Endocrinol. Metab."},{"key":"B11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/dom.13979","article-title":"Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens","volume":"22","author":"Frias","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: A randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet. Diabetes Endocrinol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: An updated meta-analysis of eight CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"B17","first-page":"d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Cochrane Bias MethodsBMJ"},{"key":"B18","doi-asserted-by":"publisher","first-page":"dgaa327","DOI":"10.1210\/clinem\/dgaa327","article-title":"GIP as a therapeutic target in diabetes and obesity: Insight from incretin Co-agonists","volume":"105","author":"Holst","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B19","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1007\/s12325-021-01637-6","article-title":"Efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus: A network meta-analysis","volume":"38","author":"Jiang","year":"2021","journal-title":"Adv. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.3390\/ijms23073451","article-title":"Glucagon-like peptide-1 receptor agonists in the management of type 2 diabetes mellitus and obesity: The impact of pharmacological properties and genetic factors","volume":"23","author":"Klen","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): A randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40261-019-00826-0","article-title":"Glucagon-like peptide-1 receptor analogues in type 2 diabetes: Their use and differential features","volume":"39","author":"Lyseng-Williamson","year":"2019","journal-title":"Clin. Drug Investig."},{"key":"B25","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s13300-020-00981-0","article-title":"The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials","volume":"12","author":"Min","year":"2021","journal-title":"Diabetes Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B29","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s12020-020-02193-9","article-title":"Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes: A systematic review and meta-analysis of 21 randomized controlled trials","volume":"68","author":"Qie","year":"2020","journal-title":"Endocrine"},{"key":"B30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2337\/dc16-0236","article-title":"Delegates of the 2nd diabetes surgery, SMetabolic surgery in the treatment algorithm for type 2 diabetes: A joint statement by international diabetes organizations","volume":"39","author":"Rubino","year":"2016","journal-title":"Diabetes Care"},{"key":"B32","doi-asserted-by":"publisher","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the international diabetes federation diabetes atlas, 9th edition","volume":"9157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B33","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: A pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11154-014-9289-5","article-title":"Effects of GLP-1 on appetite and weight","volume":"15","author":"Shah","year":"2014","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"B35","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e2116506119","DOI":"10.1073\/pnas.2116506119","article-title":"Structural determinants of dual incretin receptor agonism by tirzepatide","volume":"119","author":"Sun","year":"","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B37","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B38","doi-asserted-by":"publisher","first-page":"695182","DOI":"10.3389\/fphar.2021.695182","article-title":"Efficacy and safety of subcutaneous and oral semaglutide administration in patients with type 2 diabetes: A meta-analysis","volume":"12","author":"Zhong","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1097\/CM9.0000000000001407","article-title":"Population diversity of cardiovascular outcome trials and real-world patients with diabetes in a Chinese tertiary hospital","volume":"134","author":"Zhou","year":"2021","journal-title":"Chin. Med. J."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1016639\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T14:37:32Z","timestamp":1670510252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1016639\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":39,"alternative-id":["10.3389\/fphar.2022.1016639"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1016639","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]},"article-number":"1016639"}}